The United Kingdom and the United States have signed a key trade agreement that will preserve zero levies on British medicine products being sold in the US market.
The Terms of the Pact
Under the terms of the agreement, the UK has committed to increase spending on pharmaceuticals through the NHS. This pledge secures that duties on these key exports will stay at nothing for a period of three years.
This deal is in response to previous threats to hike import taxes on branded pharmaceutical imports, with potential rates floated reaching one hundred percent.
"This agreement with the UK strengthens the global environment for new treatments and brings much-needed balance to U.S.–U.K. pharmaceutical trade," a release noted.
Economic Impact
Pharmaceuticals constitute one of the Britain's biggest goods shipped to the US, which is easily the primary market for leading UK drugmakers.
Trade data show that in the 12 months to the end of last September, the UK sold pharmaceutical products worth billions to the US. This figure represented 17.4% of total UK exports in that timeframe.
"This guarantee safeguards employment, stimulates investment and paves the way for the UK to become a worldwide center for life sciences," a minister remarked.
Specific UK Commitments
The pact involves several key pledges from the UK:
- Revised Affordability Limit: The UK will increase the affordability limit at which it judges new medicines to be too expensive by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total health service expenditure on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Rebate Cap: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Last year, rebates topped 20%.
Broader Context
The pact follows a protracted row between the pharmaceutical industry and the ministers over drug pricing and approval rates.
The disagreement were exacerbated by assertions that US consumers were charged a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several large pharmaceutical investments in the UK have been delayed or abandoned, while multi-billion-dollar expansions have been announced toward American operations.
The Science Minister stated that the NHS needed to increase expenditure on drugs, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
